Filing Flows › Tandem Diabetes Care (TNDM) › Q1 2025
Tandem Diabetes Care (TNDM) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 30, 2025
Tandem Diabetes Care (TNDM) reported revenue of $234M for the first quarter 2025 (Q1 2025), +22% from a year earlier and -17% from the quarter before. Operating margin was -51.6%, net loss $131M (55.7% of revenue).
Tandem Diabetes Care, Q1 2025: revenue $234M (+22% year over year), operating margin -51.6%, net loss $131M, operating cash flow −$18.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $234M | -17% | +22% |
| Operating profit | −$121M | — | — |
| Net earnings | −$131M | — | — |
| Operating cash flow | −$18.3M | — | — |
What changed
Revenue was $234.4M in Q1 2025, up 22% year over year and down 17% from the previous quarter. Supplies and other was the largest line at 56% of revenue. Supplies and other added $26.8M year over year (up 25%), 63% of the total change.
Gross margin was 50.5%, up 1.1 points from a year earlier. Operating costs exceeded revenue by $120.9M, an operating margin of -51.6%. Operating expenses grew 75% against revenue growth of 22%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $130.6M, after a profit of $755K the previous quarter.
Operating cash flow was −$18.3M. Non-cash charges added back $4.3M of depreciation and amortization and $25.5M of share-based compensation. Working capital and other items added $82.5M. Capital expenditures of $3.0M exceeded it, leaving free cash flow of −$21.2M.
Questions
What was Tandem Diabetes Care's revenue in the first quarter 2025?
Tandem Diabetes Care (TNDM) reported revenue of $234M for the first quarter 2025 (Q1 2025), +22% from a year earlier and -17% from the quarter before.
Was Tandem Diabetes Care profitable in the first quarter 2025?
Operating loss was $121M (-51.6% of revenue) and net loss $131M.